Workflow
OBiO Tech(688238)
icon
Search documents
和元生物(688238) - 2022 Q4 - 年度财报
2023-04-19 16:00
Financial Performance - The company reported a net profit attributable to shareholders of RMB 39.0252 million for the year 2022[6]. - The net profit attributable to shareholders of the listed company was CNY 39.03 million, a decrease of 28.07% compared to the previous year[27]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 30.80 million, a year-on-year decrease of 24.87%[42]. - The company achieved operating revenue of CNY 291.30 million in 2022, representing a year-on-year increase of 14.26%[27]. - The company achieved total revenue of 291.30 million RMB, representing a year-on-year growth of 14.26%[162]. - The gross profit margin for the biopharmaceutical sector decreased by 6.64 percentage points to 44.72%[170]. - The gross profit margin of CDMO services is subject to fluctuations, particularly in early-stage projects, which typically have lower margins[156]. - Operating cash flow decreased by 80.40% to 21.42 million RMB, primarily due to delayed customer payments[165]. - The overall operating costs rose by 30.52% to 161.93 million RMB, aligning with the increase in revenue[165]. Share Capital and Dividends - The company plans to increase its total share capital from 493,189,000 shares to 641,145,700 shares by issuing 147,956,700 new shares to shareholders[6]. - The company will not distribute cash dividends or bonus shares for the year 2022, opting instead for a capital reserve conversion[6]. - The board of directors has approved the profit distribution plan, pending approval from the shareholders' meeting[7]. Risks and Challenges - There are no significant risks that materially affect the company's operations during the reporting period[4]. - The report includes forward-looking statements that are subject to various uncertainties and risks[9]. - The company faces risks related to client drug commercialization, which could impact CDMO service demand and profitability if projects do not progress as expected[152]. - The company is at risk of talent shortages in a rapidly growing industry, which could adversely affect R&D efforts and project execution[153]. - Increased competition in the gene therapy CDMO sector may challenge the company's market position if it fails to continuously upgrade its technology and services[155]. Research and Development - The company plans to invest 200 million RMB in research and development over the next two years to accelerate innovation[19]. - The company increased its R&D investment as a percentage of operating revenue to 11.96%, up by 2.7 percentage points from the previous year[29]. - R&D expenditure for the year was RMB 34.83 million, an increase of 47.47% year-on-year[47]. - The total R&D expenditure for the year reached approximately 34.83 million yuan, a 47.47% increase from the previous year, representing 11.96% of total revenue, up from 9.26%[127][128]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 30% based on new product launches and market expansion strategies[19]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[19]. - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in cell and gene therapy[19]. - The company is actively expanding its influence in the U.S. market through industry exhibitions, client visits, and academic presentations[101]. Product Development and Innovation - New product development includes advancements in gene editing technologies, with expected market introduction in Q3 2023[19]. - The company has established a new cell bank facility to support its product development and ensure quality control[19]. - The company has developed a new "BigAdeno" large-capacity adenoviral vector packaging system, capable of exceeding 10Kb gene carrying capacity, and has initiated several R&D production collaborations[117]. - The company is focusing on enhancing the efficacy of gene therapy vectors through various optimizations, resulting in significant improvements at both cellular and animal levels[119]. Financial Position and Assets - Total assets at the end of 2022 reached CNY 2,490.08 million, an increase of 97.09% from the beginning of the year[30]. - The net assets attributable to shareholders of the listed company grew by 136.60% to CNY 2,171.97 million by the end of 2022[30]. - Cash and cash equivalents at the end of the period were 1,243,842,147.66 RMB, accounting for 49.95% of total assets, primarily due to funds raised from stock issuance[190]. - Accounts receivable increased by 169.87% to 77,808,946.94 RMB, mainly due to delayed payments from CDMO business clients[190]. Client and Supplier Relationships - The top five customers contributed ¥97.68 million in sales, representing 33.54% of the annual total sales[177]. - The top five suppliers accounted for 2,150.58 million RMB in purchases, which is 24.07% of the total annual purchases[181]. - The company has established a broad customer base, including renowned gene therapy companies and top research institutions, enhancing its market competitiveness[144]. Industry Trends and Market Outlook - The global gene therapy market size grew from $50.4 million in 2016 to $2.08 billion in 2020, with a projected size of nearly $30.54 billion by 2025, representing a CAGR of 70% from 2020 to 2025[72]. - The Chinese CGT market is expected to reach $2.59 billion by 2025, with a CAGR of 276% from 2020 to 2025[72]. - The gene therapy industry is experiencing short-term challenges but is expected to have long-term growth potential due to the approval of multiple gene therapy drugs in 2022 and improvements in insurance coverage for these treatments[76].
和元生物:关于召开2022年度暨2023年第一季度业绩说明会的公告
2023-04-19 13:01
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 证券代码:688238 证券简称:和元生物 公告编号:2023-020 和元生物技术(上海)股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 投资者可于 2023 年 4 月 21 日(星期五) 至 04 月 27 日(星期四)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zhengquanbu@obiosh.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 和元生物技术(上海)股份有限公司(以下简称"公司")已于 2023 年 4 月 20 日披露公司《2022 年年度报告》,并将于 2023 年 4 月 27 日披露公司《2023 年第一季度报告》,为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况,公司计划于 2023 年 4 月 28 日 下午 16:00- 17:00 举 ...
和元生物(688238) - 2022 Q3 - 季度财报
2022-10-26 16:00
一、 主要财务数据 2022 年第三季度报告 证券代码:688238 证券简称:和元生物 和元生物技术(上海)股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整, 不存在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 注:"本报告期"指本季度初至本季度末 3 个月期间,下同。 (二)非经常性损益项目和金额 单位:元 币种:人民币 | 项目 | 本报告期金额 | 年初至报告期 | 说明 | | --- | --- | --- | --- | | | | 末金额 | | | 非流动性资产处置损益 | | | | | 越权审批,或无正式批准文件, | | | | | 或偶发性的税收返还、减免 | | | | | 计入当期损益的政府补助,但与 ...
和元生物(688238) - 2022 Q1 - 季度财报
2022-04-26 16:00
2022 年第一季度报告 证券代码:688238 证券简称:和元生物 和元生物技术(上海)股份有限公司 2022 年第一季度报告 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存 在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位:元 币种:人民币 | 项目 | 本报告期 | 本报告期比上年 | | --- | --- | --- | | | | 同期增减变动幅 | | | | 度(%) | | 营业收入 | 73,116,236.08 | 56.85 | | 归属于上市公司股东的净利润 | 12,069,474.76 | 28.78 | | 归属于上市公司股东的扣除非 经常性损益的净 ...